CA
DAWN

Crewe Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Crewe Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-30
Closed -$369 – 483
2023
Q3 		$369 Hold
30
– – ﹤0.01% 408
2023
Q2 		$359 Hold
30
– – ﹤0.01% 662
2023
Q1 		$402 Hold
30
– – ﹤0.01% 783
2022
Q4 		$646 Sell
30
-50
-63% -$1.03K ﹤0.01% 961
2022
Q3 		$2K Hold
80
– – ﹤0.01% 1028
2022
Q2 		$1K Buy
+80
New +$826 ﹤0.01% 1054

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Crewe Advisors's DAWN Position: Q4 2023 in Review

Crewe Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q4 2023, closing a stake of 30 shares — an estimated $369 sold.

Crewe Advisors first reported a position in DAWN in Q2 2022 and held it in 6 quarters. The position peaked at $2K in Q3 2022. 139 funds tracked by Wall St. Rank hold DAWN as of Q4 2023.

  • Crewe Advisors reported no remaining Day One Biopharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Crewe Advisors sold 30 Day One Biopharmaceuticals shares in Q4 2023, an estimated $369.
  • Crewe Advisors first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 6 quarters.
  • Crewe Advisors's Day One Biopharmaceuticals position peaked at $2K in Q3 2022.
  • 139 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2023.

Based on Crewe Advisors's 13F filing for Q4 2023, filed 9 Feb 2024.